NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today that it has received an issued patent from the Japanese
Patent Office (Japanese patent number 6722453) covering SLS-002
titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF
USE. The issued claims cover a formulation and method of
using SLS-002 to treat patients experiencing anxiety due to phobic
disorders such as: Specific Phobia, Agoraphobia, and Social
Phobia.
Additionally, Seelos has received a Notice of Allowance from the
Japanese Patent Office (Japanese patent application number
2018-124196) covering SLS-002 titled: ANXIOLYTIC COMPOSITION,
FORMULATION AND METHOD OF USE. The allowed claims cover a
formulation and method of using SLS-002 to prevent anxiety in
patients prior to medical or dental procedures.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:http://www.prnewswire.com/news-releases/seelos-announces-issuance-of-a-new-patent-and-an-additional-notice-of-allowance-in-japan-for-intranasal-racemic-ketamine-sls-002-301129742.html
SOURCE Seelos Therapeutics, Inc.